Natera Inc
Stock Watch
Stock Watch will tell you what changes at Natera Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 182.70 $ to 436.00 $ · Last price: 414.30 $ (As of: October 30, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 10/31/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Diagnostics & Research
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Natera Inc NTRA | 59.7 | – | -26.8 | 65.2 | -12.4 | 35.9 | 114.4 |
| Thermo Fisher Scientific Inc TMO | 256.1 | 38.6 | 23.4 | 41.2 | 17.9 | 3.9 | 25.8 |
| Danaher Corporation DHR | 164.0 | 43.8 | 24.0 | 59.4 | 22.9 | 2.9 | 8.8 |
| Agilent Technologies Inc A | 49.5 | 33.7 | 25.1 | 53.7 | 23.7 | 6.7 | 22.9 |
| Waters Corporation WAT | 45.4 | 55.6 | 51.3 | 56.3 | 2.8 | 7.0 | 34.9 |
| IQVIA Holdings Inc IQV | 44.8 | 32.6 | 17.0 | 33.0 | 13.6 | 5.9 | 23.5 |
| IDEXX Laboratories Inc IDXX | 43.8 | 41.3 | 27.9 | 62.5 | 31.8 | 10.4 | -12.3 |
| Illumina Inc ILMN | 35.7 | 39.8 | 30.4 | 67.9 | 18.3 | -0.8 | 138.4 |
| Mettler-Toledo International Inc MTD | 33.8 | 38.6 | 27.4 | 60.3 | 23.3 | 4.0 | 21.6 |
| Median of companies shown | 45.4 | 39.2 | 25.1 | 59.4 | 18.3 | 5.9 | 23.5 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 217 | -96 | -96 | -1.86 | -74 | 106 | 211 |
| 2017 | 211 | -134 | -136 | -2.54 | -98 | 25 | 215 |
| 2018 | 258 | -115 | -128 | -2.22 | -71 | 32 | 268 |
| 2019 | 302 | -116 | -125 | -1.79 | -63 | 279 | 583 |
| 2020 | 391 | -216 | -230 | -2.84 | -183 | 486 | 932 |
| 2021 | 625 | -468 | -472 | -5.21 | -335 | 653 | 1,236 |
| 2022 | 820 | -541 | -548 | -5.57 | -432 | 706 | 1,394 |
| 2023 | 1,083 | -446 | -435 | -3.78 | -247 | 765 | 1,442 |
| 2024 | 1,697 | -222 | -190 | -1.53 | 136 | 1,195 | 1,661 |
| 2025 | 2,306 | -310 | -208 | -1.52 | 215 | 1,712 | 2,508 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.43 | – | 476 | 53.00 | -11.30 | 53 | 35 |
| 2025: Q1 | -0.50 | – | 502 | 36.50 | -13.30 | 45 | 23 |
| 2025: Q2 | -0.74 | – | 547 | 32.20 | -18.50 | 38 | 12 |
| 2025: Q3 | -0.64 | – | 592 | 34.70 | -14.80 | 59 | 25 |
| 2025: Q4 | 0.35 | – | 666 | 39.80 | 7.10 | 74 | 38 |
| 2026: Q1 | -0.60 | – | 697 | 38.80 | -12.20 | 40 | 18 |
| 2026: Q2 | -0.47 | 36.50 | 753 | 37.70 | -8.90 | 55 | -9 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.46 | -2.02 – -0.63 | 2,911 | 3.8% | 17 |
| 12/31/2027 | -0.18 | -1.94 – 1.74 | 3,521 | 87.8% | 16 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
With these assumptions (discount rate 10.0%, terminal growth 2.5%), no growth rate between -20.0% and 60.0% per year explains today’s market value — the reverse calculation yields no meaningful figure here.
| Free cash flow (last twelve months) | $71.7M |
|---|---|
| Market cap | $59.67B |
| Free cash flow in year ten | – |
| Terminal value as a share of market value | – |
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 41.1%
- More than 10% revenue growth is expected for the coming year 18.7%
- Share count grows by less than 3% a year 11.6%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 40.6%
- Gross margin at 40% or higher and without meaningful erosion 64.9%
- Goodwill from acquisitions does not grow faster than revenue 5.6%
- Net debt below twice EBITDA 862 m net cash
- Operating cash flow covers the profits of the last three years 937 m
- Return on capital at 15% or higher, or up versus two years ago -15.0%
- Insiders hold at least 10% or are net buyers 3.0%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
5/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 30.0%
- Exp. sales growth 3Y > 5% 23.6%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 23.6%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -17.4%
- ROCE > 15% -15.0%
- Expected return > 10% 23.8%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 1,906 | 425.55 | 811,098 |
| Oct 28, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 865 | 426.87 | 369,245 |
| Oct 28, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 313 | 425.32 | 133,126 |
| Oct 28, 2026 | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell | 898 | 426.34 | 382,854 |
| Oct 28, 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 1,162 | 426.34 | 495,408 |
| Oct 28, 2026 | Rabinowitz Daniel | SEC. AND CHIEF LEGAL OFFICER | Sell | 968 | 426.34 | 412,698 |
| Oct 28, 2026 | Chapman Steven Leonard | CEO AND PRESIDENT | Sell | 3,430 | 426.34 | 1,462,348 |
| Oct 28, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 1,198 | 426.34 | 510,756 |
| Oct 28, 2026 | Sheena Jonathan | Director | Sell | 187 | 426.34 | 79,726 |
| Oct 27, 2026 | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell | 781 | 406.00 | 317,086 |
The company
About the Company
Natera, Inc. ist ein Diagnostikunternehmen, das weltweit molekulare Testdienste entwickelt und kommerzialisiert.
- CEO Insider Trades (12 Mo.)
- selling own stock
- Employees
- 6,135
- Headquarters
- Austin, TX
- Address
- 13011 McCallen Pass, 78753 Austin, United States
- Phone
- 650 980 9190
- Website
- natera.com
- IPO Date
- 07/02/2015
- ISIN
- US6323071042
Management
| Name | Title | Birth Year |
|---|---|---|
| Matthew Rabinowitz Ph.D. | Co-Founder & Executive Chairman | 1973 |
| Steven Leonard Chapman | CEO & Director | 1979 |
| John Fesko | President & Chief Business Officer | 1979 |
| Michael B. Brophy M.B.A. | Chief Financial Officer | 1980 |
| Solomon Moshkevich M.B.A. | President of Clinical Diagnostics | 1982 |
| Jonathan Sheena M.Eng. | Co-Founder & Director | 1973 |
| Olesya A. Anisimova CPA | Chief Accounting Officer | – |
| Rishi Kacker | Chief Technology Officer | – |
| Eric A. Evans Ph.D. | Chief Scientific Officer | – |
| Daniel Rabinowitz L.L.M. | Secretary & Chief Legal Officer | 1969 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/06/2026 Natera, Inc. (NTRA): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 07/06/2026 Natera, Inc. (NTRA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers SEC ↗
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.